Published in Int J Endocrinol on March 19, 2015
Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice. Evid Based Complement Alternat Med (2016) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (2004) 12.27
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab (2004) 7.96
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology (2001) 5.07
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut (2008) 3.88
Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes (1989) 3.74
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature (2013) 3.72
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA (2001) 1.90
Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer (2011) 1.89
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol (2007) 1.78
Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther (2004) 1.61
Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2004) 1.60
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol (2007) 1.58
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2008) 1.54
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) (2011) 1.45
Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia (1999) 1.36
Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes (1999) 1.36
Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol (2008) 1.32
Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. Diabetes (2004) 1.28
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 1.25
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol (2009) 1.21
Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-on-chronic liver failure. Liver Int (2008) 1.20
Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 1.11
Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol (2010) 1.09
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol (2001) 1.02
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2008) 0.98
An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol (2009) 0.95
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol (2008) 0.94
Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol (2007) 0.92
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract (2008) 0.91
Steatohepatitis and apoptosis: therapeutic implications. Am J Gastroenterol (2004) 0.89
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 0.87
Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest (2009) 0.84
Autoimmune hepatitis. Curr Gastroenterol Rep (2005) 0.76
An apoptosis biomarker for prediction of nonalcoholic steatohepatitis. Hepatology (2009) 0.76